Communiqué from Annual General Meeting
Communiqué from Annual General Meeting
Oasmia Pharmaceutical AB (publ.) VAT no SE556332-667601 held its Annual General Meeting on Friday, September 25, 2009 for the fiscal year 2008/2009 where the following resolutions were made. For more detailed information, see the complete notice for Annual General Meeting which is available at the Oasmia Pharmaceutical website www.oasmia.com
Establishment of Balance Sheet and Income Statement
The Annual General Meeting established the Balance Sheet, Income Statement, Consolidated Accounts and Financial report. It was resolved that the accumulated profit of SEK 54 625 553 shall be brought forward.
The Board of Directors
The Annual General Meeting discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2008/2009. The Meeting re-elected the Board members Bo Cederstrand, Peter Ström, Claes Piehl and Julian Aleksov. Bo Cederstrand was re-elected as chairman of the Board. In connection, the Meeting was informed that the nomination committee is discussing an expansion of the number of Board members to further widen the competence of the Board.
Remuneration to the Board and Auditors
The Annual General Meeting established that a member of the Board who is not employed by the company shall receive remuneration amounting to SEK 25 000. Remuneration to the Auditors shall be paid according to bill.
Guidelines for remuneration to senior managers
The Annual General Meeting approved the guidelines proposed by the Board for remuneration to senior managers.
Nomination committee
The Annual General Meeting approved the proposal concerning criteria for the selection of a nomination committee for the Annual General Meeting 2010.
Revision of the Articles of Association
The Annual General Meeting approved the revision of the Articles of Association proposed by the Board, concerning the regulations stating when a shareholder must be registered in the share register in order to participate at the Meeting.
Authorization for the Board to make decisions of issue of new shares and convertible debt instruments
The Meeting made a resolution to authorize the Board to, at one or more occasions, make decisions of issue of new shares and convertible debt instruments against payment in cash and/or in kind or offset, in accordance with the Board's proposal. The total number of shares issued by the authorization may not exceed 3 000 000 shares. The total number of convertibles issued by the authorization may not exceed the number of convertibles entitling to a conversion to 3 000 000 shares.
For further information, contact:
Julian Aleksov, Chief Executive Officer
Oasmia Pharmaceutical AB
Telephone: +46 (0) 18 50 54 40
E-mail: info@oasmia.com
The press release is available in PDF-format here.
